4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/Amsacrine HClfeatured/500mg/100057
商品详细MedKoo/Amsacrine HClfeatured/500mg/100057
MedKoo/Amsacrine HClfeatured/500mg/100057
MedKoo/Amsacrine HClfeatured/500mg/100057
商品编号: 100057
品牌: MedKoo
市场价: ¥3000.00
美元价: 1800.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Amsacrine HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:100057

CAS#:54301-15-4 (HCl)

Description:Amsacrine is an aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.

Price and Availability

SizePriceShipping out timeQuantity
500mgUSD 150Same Day
1gUSD 250Same Day
2gUSD 450Same Day
5gUSD 950Same Day
10gUSD 1450Same Day
20gUSD 19502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

Amsacrine HCl, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100057Name: Amsacrine HClCAS#: 54301-15-4 (HCl)Chemical Formula: C21H20ClN3O3SExact Mass: Molecular Weight: 429.92Elemental Analysis: C, 58.67; H, 4.69; Cl, 8.25; N, 9.77; O, 11.16; S, 7.46

Related CAS #:51264-14-3 (free base)54301-16-5 (mesylate)80277-07-2 (gluconate)80277-11-8 (lactate)54301-15-4 (HCl)

Synonym:acridinyl anisidide; Cains Acridine. US brand name: Amsa PD. Foreign brand names: Amekrin; Amsidine; Amsidyl; Lamasine. Abbreviations: AMSA; mAMSA. Code names: CI880; SN11841.

IUPAC/Chemical Name:N-(4-(acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide hydrochloride

InChi Key:WDISRLXRMMTXEV-UHFFFAOYSA-N

InChi Code:InChI=1S/C21H19N3O3S.ClH/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21;/h3-13,24H,1-2H3,(H,22,23);1H

SMILES Code:CS(=O)(NC1=CC=C(NC2=C(C=CC=C3)C3=NC4=CC=CC=C42)C(OC)=C1)=O.[H]Cl

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#YYP30918

QC Data:
View QC data: current batch, Lot#YYP30918

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

Related:51264-14-3 (Amsacrine) 54301-15-4 (Amsacrine HCl).

References

1: Jangir DK, Kundu S, Mehrotra R. Role of minorgroove width and hydration pattern on amsacrine interaction with DNA.PLoS One. 2013 Jul 29;8(7):e69933. doi: 10.1371/journal.pone.0069933.Print 2013. PubMed PMID: 23922861; PubMed Central PMCID: PMC3726726.

2: Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M,Tomiska M, Horky O, Pospisilova S, Mayer J. Combination of fludarabine,amsacrine, and cytarabine followed by reduced-intensity conditioning andallogeneic hematopoietic stem cell transplantation in patients withhigh-risk acute myeloid leukemia. Ann Hematol. 2013 Jun 1. [Epub aheadof print] PubMed PMID: 23728608.

3: Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C,Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, ServeH, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD,Schetelig J, Bornhäuser M, Ehninger G. High-dose cytarabineconsolidation with or without additional amsacrine and mitoxantrone inacute myeloid leukemia: results of the prospective randomized AML2003trial. J Clin Oncol. 2013 Jun 10;31(17):2094-102. doi:10.1200/JCO.2012.46.4743. Epub 2013 Apr 29. PubMed PMID: 23630210.

4: Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J,Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A,Wei A. Fludarabine, cytarabine, granulocyte-colony stimulating factorand amsacrine: an effective salvage therapy option for acute myeloidleukemia at first relapse. Leuk Lymphoma. 2013 Feb;54(2):336-41. doi:10.3109/10428194.2012.713479. Epub 2012 Sep 8. PubMed PMID: 22812445.

5: Jangir DK, Dey SK, Kundu S, Mehrotra R. Assessment of amsacrinebinding with DNA using UV-visible, circular dichroism and Ramanspectroscopic techniques. J Photochem Photobiol B. 2012 Sep 3;114:38-43.doi: 10.1016/j.jphotobiol.2012.05.005. Epub 2012 May 18. PubMed PMID:22677564.

6: Ketron AC, Denny WA, Graves DE, Osheroff N. Amsacrine as atopoisomerase II poison: importance of drug-DNA interactions.Biochemistry. 2012 Feb 28;51(8):1730-9. doi: 10.1021/bi201159b. Epub2012 Feb 10. PubMed PMID: 22304499; PubMed Central PMCID: PMC3289736.

7: Attia SM. Molecular cytogenetic evaluation of the mechanism ofgenotoxic potential of amsacrine and nocodazole in mouse bone marrowcells. J Appl Toxicol. 2013 Jun;33(6):426-33. doi: 10.1002/jat.1753.Epub 2011 Nov 11. PubMed PMID: 22081495.

8: Devi ML, Chandrasekhar KB, Surendranath KV, Rao BM, Narayana MB. Avalidated stability-indicating RP-HPLC assay method for Amsacrine andits related substances. J Chromatogr Sci. 2011 Aug;49(7):489-94. PubMedPMID: 21801478.

9: Wilhelm C, Neubauer A, Burchert A. Poor-risk cytogenetics may beassociated with inferior outcome after fludarabine, cytarabine, andamsacrine reduced intensity conditioning in patients with high-riskacute myeloid leukemia. Leuk Lymphoma. 2011 Oct;52(10):2031-5. doi:10.3109/10428194.2011.588760. Epub 2011 Jun 24. PubMed PMID: 21702642.

10: Zhang L, Guo Y, Wang J, Wang X, Han G, Ou W, Xu Y, Zhang X. Assistedsonodynamic damage of bovine serum albumin by metronidazole underultrasonic irradiation combined with photosensitive antitumor drug-Amsacrine.J Photochem Photobiol B. 2010 Jan 21;98(1):61-8. doi:10.1016/j.jphotobiol.2009.11.005. Epub 2009 Nov 22. PubMed PMID:20006932.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。